Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009
Date:7/25/2008

DETROIT, July 25 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) posted net sales for the first quarter of Fiscal 2009, ended June 30, 2008, of $108.3 million, as compared to $35.4 million for the corresponding period of Fiscal 2008. This represents an increase of 206% over the first quarter of Fiscal 2008. Pre-tax income grew to $14.6 million for the first quarter of Fiscal 2009 as compared to a pre-tax income of $9.6 million during the corresponding period of Fiscal 2008, while net income increased by 11% to $9.4 million in the first quarter of Fiscal 2009, as compared to $8.5 million in the first quarter of Fiscal 2008.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "Our sales results for the first quarter are primarily due to sales of distributed products launched by the Company during the fourth quarter of Fiscal 2008 under the distribution and sale agreement with Sun Pharma and, to a lesser extent, sales of other products launched in Fiscal 2008 under the marketing agreements with Sun Pharma as well as growth in sales of our own manufactured products."

Mr. Movens added, "Though distributed products launched in fourth quarter Fiscal 2008, remained a significant driver of our sales, first quarter Fiscal 2009 had solid growth on our overall product line over the corresponding period of Fiscal 2008. We continue to work towards improved market share of both new and existing products."

"Our strategy remains to grow the business appropriately by utilizing all of our diverse paths of development. During Fiscal 2008, the weight of distributed product sales significantly increased. This trend will most likely continue on a short-term basis. Overall, we are pleased with the directio
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
3. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
4. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
5. Pennsylvania Governor Rendell Breaks Ground for Global Pharmaceutical Services Companys North American Headquarters
6. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
7. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
8. Sonus Pharmaceuticals Receives Favorable NASDAQ Decision
9. Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
10. Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering
11. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Rogne Bioscience, ... Francisco Bay Area , has acquired a licence ... Oxford,s commercialisation company. The potent anti-inflammatory activity of the ... at the University of Oxford,s Sir William Dunn ... which has raised over $1.5 million in seed financing, ...
(Date:7/31/2014)... ALBANY, New York , July 31, 2014 /PRNewswire/ ... published by Transparency Market Research "Electrodes for Medical Devices ... Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, ... Share, Growth, Trends and Forecast, 2013 - 2019," the ... USD 633.6 million in 2012 and is estimated to ...
(Date:7/31/2014)... -- Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel ... supply industries, today reported financial results for the ... quarter with $33.6 million in cash and highly ... quarter Senomyx achieved another important milestone with the ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Held at ... patients with an overview of the disease and its ... drug side effects, as well as updates on the ... to Dr. Sandy Srinivas for organizing this educational opportunity,” ... kidney cancer. “Sandy and her colleagues have put together ...
Breaking Biology Technology:Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... http://www.cordblood-america.com ) focused on bringing the life saving ... said today that it believes the executive order signed ... of stem cell research is a significant move forward ...
... Cynvec LLC, a privately held biotechnology company focused on ... of the sindbis viral vector, today announced that Frank ... the Cowen and Company 29th Annual Health Care Conference ... p.m. ET. About Cynvec LLC , ...
... March 9 Merrimack Pharmaceuticals, Inc., a privately held ... novel treatments for cancer and autoimmune disease, today announced ... Vice President and Chief Scientific Officer and Edward (Tad) ... "Ulrik and Tad have both played critical roles ...
Cached Biology Technology:Cord Blood America Sees Significant Positives in President Obama's Lifting of Stem Cell Funding Restrictions 2Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development 2
(Date:8/1/2014)... two Simon Fraser University research associates, cite new ... collaborate closely on minimizing damage to the natural ... Maureen Ryan, David H. Smith Conservation Research Fellows ... international co-authors of the newly published research in ... , Shale gas development is the extraction of ...
(Date:7/31/2014)... prestin was found to be a key gene responsible for ... the hair cells of the inner ear that contracts and ... an antique phonograph horn, amplify sound waves to make hearing ... in the advanced online edition of Molecular Biology and ... has also independently evolved to play a critical role in ...
(Date:7/31/2014)... the National Science Foundation (NSF), counters a widely-held ... warming, indicating instead that certain Arctic lakes store ... atmosphere. , The study, published this week ... thermokarst lakes, which occur as permafrost thaws and ... water, converting what was previously frozen land into ...
Breaking Biology News(10 mins):Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3Certain Arctic lakes store more greenhouse gases than they release 2
... HOBOKEN, N.J. (June 23, 2010) An estimated 60 ... commonly known as hay fever, according to the American Academy ... allergic inflammation of the nasal airways that causes itching, swelling, ... the June 14, 2010 issue of Phytotherapy Research ...
... scientists from the University of Nevada, Reno, DRI, Arizona ... from a two-week expedition to Guatemala,s tropical high-mountain Lake ... the algae blooms that have assailed the ecosystem and ... lake,s water is contaminated with watershed runoff and waste ...
... In what is believed to be the largest review of the ... more likely to clump faster than others, scientists at Johns Hopkins ... they say likely control that bodily function. "Our results give ... from these genes, to develop tests that could help us identify ...
Cached Biology News:Study demonstrates pine bark naturally reduces hay fever symptoms 2Study demonstrates pine bark naturally reduces hay fever symptoms 3American team of scientists help protect Guatemala's Lake Atitlan 2American team of scientists help protect Guatemala's Lake Atitlan 3Genetic septet in control of blood platelet clotting 2Genetic septet in control of blood platelet clotting 3
...
... is collected off the clot from fasted Cynomolgus monkeys ... Available Anticoagulants: N-02: Citrate ... N-08: Potassium Oxalate N-10: EDTA (Na) ... N-07: CPD N-09: K3EDTA N-11: ...
3'-O-Methylguanosine 5'-Triphosphate, Sodium, 1 umol. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
Recombinant Viral CCI/Fc Chimera, CF...
Biology Products: